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ABSTRACT
The recent advances in identification of the molecular mechanisms related to 
tumorigenesis and angiogenesis, along with the understanding of molecular alterations 
involved in renal cell carcinoma (RCC) pathogenesis, has allowed the development of 
several new drugs which have revolutionized the treatment of metastatic renal cell 
carcinoma (mRCC). 
This process has resulted in clinically significant improvements in median overall 
survival and an increasing number of patients undergoes two or even three lines of 
therapy. Therefore, it is necessary a long-term perspective of the treatment: planning 
a sequential and personalized therapeutic strategy to improve clinical outcome, 
the potential to achieve long-term response, and to preserve quality of life (QOL), 
minimizing treatment-related toxicity and transforming mRCC into a chronically 
treatable condition.
Because of the challenges still encountered to draw an optimal therapeutic 
sequence, the main focus of this article will be to propose the optimal sequencing of 
existing, approved, oral targeted agents for the treatment of mRCC using evidence-
based data along with the knowledge available on the tumor behavior and mechanisms 
of resistance to anti-angiogenic treatment to provide complementary information 
and to help the clinicians to maximize the effectiveness of targeted agents in the 
treatment of mRCC.
INTRODUCTION
Renal cell carcinoma (RCC) has seen in last 
years a rapid and continuous increase of new cases [1]. 
Approximately a quarter of patients with RCC presents 
with locally advanced or metastatic disease at diagnosis, 
and about 20-40% of those with confined primary tumor 
will develop metastatic disease [2, 3] .
The treatment of metastatic renal cell carcinoma 
(mRCC) has been revolutionized over the past 10 years, 
with the development of several new drugs, whose use has 
resulted in clinically significant improvements in median 
overall survival compared with the previous treatment 
options, limited to cytokines such as interleukin-2 and 
interferon α (IFN-α) [4]. These immunotherapies showed 
poor efficacy and severe dose-limiting toxicities [5, 6]. 
The recent advances in identification of the 
molecular mechanisms related to tumorigenesis, 
angiogenesis, cell growth and proliferation, along with 
the understanding of molecular alterations involved in 
RCC pathogenesis [7-12], allowed to identify targets of 
clinical interest: the vascular endothelial growth factor 
(VEGF) and its receptors (VEGFr), the mammalian target 
of rapamycin (mTOR) signaling pathway, the fibroblast 
growth factor (FGF) and its receptor (FGFr), the hypoxia-
inducible factors (HIFs) and Akt activation.
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Based on these known signaling pathways, targeted 
systemic treatments have been specifically designed and 
approved: the humanized anti-VEGF monoclonal antibody 
bevacizumab [13, 14] in combination with IFN-α, four 
multitargeted tyrosine kinase inhibitors (TKIs): sorafenib, 
sunitinib, pazopanib and axitinib; and two kinase 
inhibitors of mTOR, temsirolimus and everolimus (Figure 
1). 
The introduction of these several new targeted 
agents raises many questions on how to use them in order 
to maximize their effectiveness and offer to the patient a 
greater number of therapeutic opportunities, in the most 
appropriate setting [15-18]: these are groups of agents 
with a different mechanism of action and consequently 
different toxicity, in the absence of molecular parameters 
able to predict response and resistance, and with few direct 
comparisons between them [19]. 
The data available often derived from studies 
planned to obtain drug registration, where different agents 
are compared with placebo or IFN-α, with little indirect 
differences among them in terms of progression-free 
survival (PFS) and overall survival (OS) [20]. 
Furthermore, although targeted agents have 
demonstrated PFS benefit, durable responses are rare and 
most patients with mRCC eventually experience disease 
progression [21, 22].
Therefore, in the new era of targeted therapies for 
the treatment of mRCC, it would be appropriate to plan 
a sequential and personalized therapeutic strategy to 
improve clinical outcome, to potentially achieve long-
term response, and to preserve quality of life (QOL), 
minimizing treatment-related toxicity and transforming 
mRCC into a chronically treatable condition.
The main focus of this article will be to propose the 
optimal sequencing of existing, approved, oral targeted 
agents for the treatment of metastatic renal clear cell 
carcinoma, the most frequent subtype of sporadic RCC 
(70-85%) [23], although it remains an area of ongoing 
research, through the identification of novel pathways, 
new data from early clinical trials and emerging immune 
based therapies.
EVIDENCE-BASED OUTLINE OF 
SEQUENCES OF TARGETED AGENTS:
First-line treatment
In the first-line treatment of mRCC population 
VEGF-targeted agents have improved patient outcomes 
compared with the previous cytokines-based standard of 
care.
Current evidence-based guidelines recommend 
three drugs as first-line treatment for patients with good-
intermediate risk: bevacizumab (combined with IFN-α), 
sunitinib and pazopanib [3].
All three agents have demonstrated PFS 
prolongation, in phase III trials over either IFN-α or 
placebo [24-32].
First-line temsirolimus has demonstred activity in 
patients with poor prognosis [33]. 
Sunitinib, a multitarget oral TKI that inhibits the 
VEGF and PDGF receptors, was compared to IFN-α in a 
randomized trial of untreated patients, showing improved 
median PFS (11 vs 5 months) and median OS (26 vs 21 
months) and a response rate over 40% [30]. These results 
allowed to set sunitinib as a standard treatment in this 
setting.
Pazopanib, another oral multitarget TKI with 
inhibitory activity against VEGF and PDGF receptor, was 
compared, head-to-head, with sunitinib, in a randomized 
non-inferiority trial in first-line setting (COMPARZ): the 
pazopanib and sunitinib groups had similar median PFS 
(8.4 months for pazopanib versus 9.5 months for sunitinib; 
HR, 1.047, 95% CI, 0.898-1.220) [34].
There were no significant differences in response 
rates and OS between the two agents (median overall 
survival 28.4 months in the pazopanib group and 29.3 
months in the sunitinib group) [35].
The analyses of QOL were in favor of pazopanib.
The improved safety profile and QOL of pazopanib 
were confirmed by “The Preference Study of Pazopanib 
Versus Sunitinib in Advanced or Metastatic Kidney 
Cancer” (PISCES) which evaluated patients’ preference 
for pazopanib or sunitinib in treatment-naive patients with 
mRCC: patients were randomized to pazopanib for 10 
weeks, and after 2 weeks of washout, to sunitinib for 10 
weeks, or to the opposite sequence. 
At 22 weeks, patients completed a questionnaire 
assessing their preferences: significantly more patients 
preferred Pazopanib (70%) over Sunitinib (22%); 8% did 
not prefer any agent [36].
These findings have shown Sunitinib and Pazopanib 
are agents with similar efficacy in first-line treatment, but 
the use of Pazopanib as first line therapy, in patient with 
good-intermediate risk mRCC, seems more convenient for 
his better safety profile. 
Second-line treatment
Most patients initially treated with an anti-VEGF 
therapy in first-line setting, eventually develop resistance 
and subsequent disease progression. [37, 38]
Current post first-line therapies for mRCC, target the 
VEGFr and mTOR pathways. Approved treatment options 
include sorafenib, axitinib and everolimus. Sunitinib is 
also an option if it was not previously administered [3].
Sorafenib is a multikinase inhibitor of multiple 
growth factor receptors as VEGFr, PDGFr, Flt-3 and 
c-Kit and Raf-1, a member of RAF/MEK/ERK signaling 
pathway [39]; axitinib is a next-generation TKI, potent and 
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highly selective for the VEGF receptor 1, 2 and 3 [40-
42]; everolimus is a mammalian target of mTor inhibitor 
(mTORi) [43]. 
The choice of a second-line treatment represents a 
controversy about the optimal sequence to be proposed: 
in the VEGFr TKI-resistant setting, is it better to continue 
treatment with a different VEGFr-TKI or to overcome 
cross-resistance by switching to a drug with a different 
mechanism of action? (i.e. a mTORi)? [16-18, 44, 45] .
Although switching to a different signalling pathway 
appears to be rational, current data support the use of both 
mTORi and TKI: they are associated with similar median 
progression-free survival (PFS) of about 4-5 months. 
However, while axitinib is compared with another 
TKI in the AXIS trial, everolimus, in the RECORD-1 trial, 
is compared with placebo. 
The AXIS trial is a phase III RCT study comparing 
axitinib and sorafenib as second line treatment in patients 
with advanced clear cell RCC, after a prior systemic 
regimen including sunitinib (54%), cytokines (35%), 
bevacizumab (8%) or temsirolimus (3%). Although in 
the overall population, patients treated with axitinib 
experienced a significantly longer PFS than those on 
sorafenib (6.7 vs 4.7 months; p<0.0001), in the patients 
subgroup with disease progression on sunitinib, PFS 
was shorter with both axitinib and sorafenib (4.8 vs 
3.4 months; p<0.0107) than in patients pretreated with 
cytokines (12.1 vs 6.5 months; p<0.0001) [46]. 
No OS differences in either axitinib and sorafenib 
group was detected [47, 48]. 
As regards mTORi after the VEGFr inhibition-based 
therapy, data are provided by the RECORD-1 phase trial. 
In this study patients progressing on first line therapy were 
randomized to receive everolimus or placebo. 
One or two previous VEGFr inhibition based 
therapies were permitted, including bevacizumab and 
cytokines. For this reason the results should be interpreted 
with caution because only 21% of study population were 
pure second-line therapy progressing after first-line 
treatment with sunitinib. In this subgroup median PFS was 
4.6 with everolimus vs 1.8 months with placebo. 53% of 
patients received one TKI and cytokine (PFS 5.2 vs 1.8 
months) and 26% were third line after two TKIs (PFS 4 vs 
1.8 months) [49-52].
Since number and type of previous treatments 
are crucial, the subsequent RECORD-4 was planned, 
Figure 1: Signaling pathways inhibition by targeted agents in mRCC. RCC is a highly vascularized tumor type. The chronic 
angiogenesis is required for growth of these tumors. Under normal conditions HIF (hypoxia inducible factor) is constitutively degraded. 
HIF promotes transcription of gene involved in the angiogenesis-pathway and tumor progression such as VEGF, PDGF and TGF-alfa. 
Inactivation of the von Hippel-Lindau (VHL) gene leads to accumulation of HIF transcription factors and subsequent activation of several 
mediator of angiogenesis. Also the activation of the mammalian target of rapamycin (mTOR) signaling pathway may result in HIF 
accumulation.  Temsirolimus and everolimus are kinase inhibitors of mTOR complex 1 (mTORC1); bevacizumab is a humanized 
anti-VEGF monoclonal antibody; sorafenib, sunitinib, pazopanib and axitinib are multikinase inhibitor (TKIs) of growth factor receptors 
involved in the activation of angiogenesis-related pathways.
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a phase II trial of only second-line everolimus, which 
enrolled patients into 3 subgroups based on prior first-line 
therapy: sunitinib, other anti-VEGF agents (sorafenib, 
bevacizumab, pazopanib, other) or cytokines. Median PFS 
was 5.7 months (3.7-11.3) with prior sunitinib, 7.8 months 
(5.7-11.0) with prior other anti-VEGFs and 12.9 months 
(2.6-NE) with prior cytokines (preliminary data) [53].
To date there is no direct comparison between the 
two drugs, axitinib and everolimus, in the post-VEGFr-
TKI second-line setting.
Making an indirect comparison between the two 
mentioned studies in order to identify a drug supported by 
further evidences, we can summarize that:
- The median PFS with axitinib and everolimus 
in patients with disease progression after sunitinib in first 
line setting is similar (4.8 months axitinib vs 4.6 months 
everolimus); but in the AXIS trial axitinib has an active 
comparator (sorafenib), while everolimus is compared 
with placebo; 
- In the AXIS trial all population of patients 
treated with axitinib or sorafenib were pure second-line; 
in RECORD-1 trial patients were previously treated 
with one or also two lines of therapy. The final data from 
RECORD-4, with only second-line everolimus, are still 
expected.
- Patients randomized to the axitinib arm in the 
AXIS trial, in absence of adverse events, could have 
undergone an increase in dose (with potential increased 
effectiveness), while patients in Everolimus arm in 
RECORD-1 trial did not undergo this dose escalation. 
- No OS difference in AXIS trial was detected. 
In RECORD-1, patients in treatment with placebo 
were allowed to cross over to everolimus upon disease 
progression. Accordingly, OS data are conditioned by the 
possibility of cross-over. 
The first trial that provides a direct comparison 
between agents with different mechanisms of action is 
the INTORSECT study; in this trial mRCC patients who 
had progressed on first-line sunitinib, were randomized to 
temsirolimus, an mTORi, or sorafenib, a VEGFr TKI.
The difference in median PFS was no statistically 
significant; median OS was in favor of sorafenib (16.6 vs 
12.3 months; p = 0.014) [54].
This could suggest an advantage for the VEGFr 
TKI-VEGFr TKI sequence compared to VEGFr TKI-
mTORi sequence, but it really does not clarify the 
controversy since it compares two treatments that do not 
represent the best option in the second-line setting.
A study investigating sequential therapies is the 
RECORD-3 trial. In this phase 2 study, patients were 
randomized to first line everolimus followed by second-
line sunitinib or the opposite sequence, sunitinib followed 
by everolimus. Results of final analysis do not lead to 
any change in the standard sequence of sunitinib on first-
line followed in second-line by everolimus at disease 
progression (PFS 21.7 months for everolimus→sunitinib 
Figure 2: Evidence-based therapeutic algorithm.
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and 22.2 months for sunitinib→everolimus; median OS 
22.4 months for everolimus→sunitinib and 29.5 months 
for sunitinib→everolimus [55, 56].
Also the randomized phase 3 SWITCH-I trial 
investigating the sequential use of two treatments: 
sunitinib followed by sorafenib versus sorafenib followed 
by sunitinib in patients with mRCC without previous 
treatment, does not change the current guidelines since 
there was no significant difference in total PFS, first-line 
PFS, OS and disease control rate between the two arms 
[57].
Although there are no data about direct comparison 
between everolimus and axitinib, summarising the 
available evidence it can be stated that the AXIS trial 
confirmed the activity of two TKI agents used sequentially 
(TKI-TKI sequence); RECORD-1 and preliminary 
RECORD-4 results show the clinical benefit of everolimus 
in the second line setting but they haven’t an active 
comparator; results of INTORSECT trial that compared a 
VEGF-TKI with an mTORi as second-line (TKI-mTORi 
sequence), are not directly transferable in clinical practice.
We can conclude that both everolimus and axitinib 
are effective options after first-line VEGFr-TKI failure, but 
the absence of head-to-head comparisons, doesn’t solve 
the controversy for the choice of treatment at present.
Sorafenib might be still considered as an alternative 
option. 
Treatment beyond second line
Most data related to third-line treatments result 
from retrospective cohort studies and subgroup analysis: 
comparative retrospective assessment of the sequence 
TKI-TKI-mTORi versus TKI-mTORi-TKI suggests 
superiority of TKI-TKI-mTORi [58]; subgroup analysis 
within the RECORD-1 trial assessed everolimus as a 
third-line agent exhibiting a significant benefit regarding 
PFS versus placebo (4.0 mo PFS vs 1.8 mo; HR: 0.32; p < 
0.01), and it is thus in favor of TKI-TKI-mTORi sequence 
[52].
Treatment in the third-line setting was assessed for 
the first time in the GOLD trial. In this phase 3 study, 
patients who received one previous VEGF-TKI inhibitor 
and one previous mTORi were randomly assigned to 
receive dovitinib (an oral tyrosine-kinase inhibitor that 
inhibits VEGFr and FGFr) or sorafenib: PFS difference 
between sorafenib and dovitinib was not statistically 
significant (3.6 vs 3.7 months, respectively; HR: 0.86 
[0.72-1.04]; p = 0.063). Interim OS analysis was also 
similar in the two arms (11.0 vs 11.1 months, respectively; 
HR: 0.96 [0.75-1.22]) [59].
This study support the re-treatment with VEGF TKI 
in third-line, after one previous TKI-mTORi sequence 
(TKI-mTORi-TKI sequence). 
There is also evidence that in patients who have 
progressed on prior targeted therapy with sunitinib and 
another TKI or mTORi, the “re-challenge” with sunitinib 
seems to have a clinical benefit, although with shorter 
progression-free survival with respect to the first-line 
treatment [60-63].
These data support the hypothesis that resistance to 
targeted therapy could be transient. 
OUTLINE OF AN EVIDENCE-BASED 
THERAPEUTIC ALGORITHM
The optimal sequence of target agent for the 
treatment of mRCC is not well defined. 
Assessing the evidence from latest trial, using 
currently approved oral VEGFR-TKI and mTORi for 
mRCC, we developed an algorithm, highlighting the 
strengths of each agents to support his eventual choice 
(Figure 2).
At the time of the choice of first-line therapy we 
must primarily take into account primarily the potential 
efficacy of the drug for the individual patient or the 
subsequent treatment options?
Given the increased survival of patients with 
advanced disease and that an increasing number of patient 
is able to undergoes two or even three lines of therapy, it 
is necessary a long-term vision and, therefore, planning is 
better than improvising.
Basing on current drug labels, we can choose 
between two sequential strategies, which is the best: TKI/
TKI/mTORi sequence or TKI/mTORi/TKI sequence?
Unfortunately, to date there are no consistent clinical 
data to support a clear and strong a sequence rather than 
another.
Considering the individual drugs, with reference to 
the first line of treatment, the oral options available today 
are sunitinib and pazopanib. Both of them have shown 
equal effectiveness, so it could be use of pazopanib for its 
better tolerability.
In second line both everolimus and axitinib are 
associated with similar median PFS: everolimus as 
a second and third-line therapy show an increase of 
PFS versus placebo in the soubgroup analysis within 
RECORD-1 trial. 
However the data from AXIS and INTORSECT 
trials suggested that patients treated with previous TKI 
may respond to another TKI in second line and cross-
resistance may not appear. 
To underline that axitinib has an active comparator 
(sorafenib), as opposed to everolimus (compared with 
placebo).
Unfortunately it is not possible today to administer 
today axitinib after pazopanib and this precludes the 
possibility of using a sequence potentially very effective. 
Given the similarity between sunitinib and pazopanib, it 
would be desirable that this may become feasible in the 
near future.
Treatment for third-line setting depends largely on 
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the choices made previously (Figure 2).
In these TKI-refractory patients it would be 
appropriate to draw clinical trials with direct comparisons 
between the drugs, comparing a TKI such as axitinib with 
a mTORi such as everolimus. This would add important 
data to choose the best therapeutic sequence.
However, for the decision-making process, should 
the clinicians consider only evidences arising from 
individual clinical trials or should they consider also other 
factors, such as those addressing resistance mechanisms 
and tumor behavior?
OUTLINE OF AN ALGORITHM DRIVEN 
EVEN BY SCIENTIFIC RATIONALE AND 
TUMOR BEHAVIOR
Because of the challenges still encountered to 
draw an optimal therapeutic sequence, the integration 
of evidence-based data with knowledge available about 
tumor biology could provide complementary information 
and help clinicians to maximize the effectiveness of 
targeted agents in the treatment of mRCC.
We have tried to do it starting from the central role 
of angiogenesis in the pathogenesis of renal tumor. RCC 
is a hyper-vascular tumor and VEGF have a key role as 
mediator of angiogenesis in this tumor [64, 65].
Anti-angiogenic drugs typically have transitory 
efficacy: they produce more or less durable responses, 
followed by disease progression due to the development 
of resistance to therapy [37, 38].
From a clinical point of view, indeed, in same 
patients anti-angiogenic drugs can achieve a good control 
of the disease for long periods, conversely in other patients 
there is a very rapid disease progression [66, 67].
We know from literature that resistance to anti-
angiogenic treatment is mainly caused by the onset of 
adaptive mechanisms of cancer cells. 
As a response to the inhibition of angiogenesis 
by VEGF pathway inhibitors, tumor cells promote the 
Figure 3: Evidence-based therapeutic algorithm driven also by scientific rationale and tumor behavior.
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transcription of pro-angiogenic factors [68, 69], the 
recruitment of vascular progenitor cells [70-72] and the 
increase of the coverage of tumor vessels by pericytes to 
maintain blood vessels functioning [73-75].
These resistance mechanism may be mediated by the 
activation of angiogenesis-related pathways independent 
of VEGFR and PDGFR, which are inhibited by first-line 
anti-angiogenic drugs [76, 77].
For instance the slow progression under the 
treatment with sunitinib or pazopanib could be associated 
with a low capacity to develop adaptive mechanism. 
We suppose that in patients with slow progression 
tumor is still VEGF-dependent. 
Therefore we might overcome this transitory 
resistance by a wider spectrum of receptor inhibition 
(i.e. sorafenib which blocks VEGFR, PDGFR, Flt-3, 
c-Kit and Raf-1) or by a stronger inhibition through more 
potent drugs (i.e. axitinib, which has a stronger inhibitory 
potency in terms of IC50 [78, 79]) .
Since AXIS trial provided strong data about the 
superiority of axitinib over sorafenib in this setting of 
patients, axitinib should be the best option as second-
line treatment for patients experiencing slow progression 
during firs-line sunitinib or pazopanib.
The patients who received a TKI and subsequently 
a different TKI, could undergo a third-line treatment with 
a further TKI or the mTORi everolimus. 
However the use of a third-line TKI (i.e. sunitinib 
or sorafenib) after two previous lines of TKIs is not 
supported by strong evidence-based data. Conversely 
the use of everolimus after TKIs in first and second-line 
treatment met favorable outcomes in RECORD-1 trial.
Patients who develop a rapid progression during 
firs-line TKI may have an intrinsic primary resistance to 
Figure 4: Promising therapeutic algorithm in the near future. Nivolumab and cabozantinib are superior to everolimus in patients 
who have failed one line or more of VEGF targeted therapy (CheckMate 025 study; METEOR study). Nivolumab showed delayed benefit 
in PFS versus everolimus. The progression-free survival curves has a late separation in the study. Therefore it would seem reasonable to 
use it in fit patients with slow progression. Cabozantinib is a multi-tyrosine kinase inhibitor. For its impressive PFS versus everolimus 
(cabozantinib median PFS 7.4 mo; everolimus median PFS 3.8 mo) should be considered for patients with rapid progression. No trials 
have compared these two experimental agents directly against axitinib in the second-line setting, where axitinib showed no OS advantage. 
Survival advantage and tolerability profile of nivolumab over everolimus makes it a valid option also versus axitinib.
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anti-angiogenic drugs, so that the resistance mechanism 
would not be adaptive. Thus in these patients we should 
address a different pathway.
mTOR inhibition by everolimus could be the most 
valid option as second-line treatment.
Accordingly for third-line treatment in this subset 
of patients a change of mechanism of action appears more 
reasonable. So after first-line TKI and second-line mTORi, 
a different TKI could be chosen as third-line treatment. 
Sunitinib is supported by retrospective studies about 
rechallange. As an alternative option sorafenib is sustained 
by data from the GOLD study (Figure 3).
EMERGING TREATMENT
Ongoing trials and other recently concluded [80-83] 
continue to research new therapies and to elucidate the 
optimal sequence of the known ones.
Recently, Immunoncology, represent a new and 
promising frontier for many malignancies, such as RCC.
The aim of Immunotherapy is to improve the 
organism’s competence to direct the immune system 
against cancer cells.
The normal immune system requires T cell 
activation for its activity; some immunomodulatory 
molecules such as cytotoxic T-lymphocyte associated 
antigen-4 (CTLA-4) and programmed death-1 (PD-1), are 
involved in the mechanism for T cells activation [84, 85]. 
They are inhibitory molecules, dysregulated in 
several cancer, resulting in defective ability of immune 
system to react against tumor cells.
As a consequence, checkpoint inhibitors have been 
developed and are under evaluation [86-92].
Nivolumab, a fully human IgG4 monoconal 
antibody directed against PD1, demonstrated effectiveness 
in patients with metastatic melanoma and non-small cell 
lung cancer.
In a phase II trial three nivolumab doses (0.3, 
2 or 10 mg/kg IV Q3W) have been assessed in mRCC 
patients pretreated with VEGFR TKIs, mTORi and 
immunotherapy. No dose-response relationship was 
detected for PFS; median OS was 18.2 months by the 0.3 
mg/kg dose and was not reached by other doses [93].
Basing on data from CheckMate 016 trial, a phase 
I study of nivolumab + ipilimumab (a human CTLA-4-
blocking antibody) in patients with mRCC [94, 95], a 
phase III trial was designed to evaluate nivolumab + 
ipilimumab compared with sunitinib monotherapy for 
previously untreated mRCC has recently been planned 
[96].
Recently the results of two pivotal, randomized, 
phase 3 trial, about nivolumab and cabozantinib, 
respectively, compared with everolimus have been 
published: both provide substantial benefit in patients 
treated with previous VEGF targeted therapy.
The first, CheckMate 025, an open-label phase 3 
trial, investigates nivolumab versus everolimus in patients 
who have failed one or more anti-VEGF therapy.
The median PFS was similar (4.6 months with 
nivolumab and 4.4 months with everolimus) while 
Nivolumab showed considerable OS advantage and 
tolerability over everolimus (OS 25.0 months with 
nivolumab and 19.6 months with everolimus) [97].
The second randomised phase 3 trial (METEOR) 
compared everolimus with cabozantinib, a small-molecule 
tyrosine kinase inhibitor of MET, VEGFR2 and AXL. The 
setting tested was the second-line after failure of one line 
or more of VEGF targeted therapy.
Cabozantinib showed superior PFS (7.4 mo) versus 
everolimus (3.8 mo). Grade 3 or 4 adverse events were 
more numerous in cabozantinib sub-group (68%) than 
everolimus-group (58%).
In the interim analysis is evident a trend of 
cabozantinib toward an OS advantage but the final planned 
mature OS data is expected in 2016 [81].
Both these new promising drugs, nivolumab and 
cabozantinib, not yet be used in the clinical practice. With 
their next introduction, a promising therapeutic algorithm 
will be available in the near future (Figure 4).
CONCLUSIONS
Physicians now have many more tools to improve 
outcomes of mRCC.
Planning the appropriate and personalized sequence 
of targeted agents may help to achieve the best clinical 
outcome in these patients by the maximum number of 
available targeted agents.
Given the short differences in median PFS observed 
between treatments, in the absence of clinical trials 
with direct comparisons between the drugs, the optimal 
therapeutic sequence is still under investigation. 
Our opinion is that, in addition to evidences from 
clinical trials, other factors must be also considered for 
decision making such as the safety profile of drugs [98, 
99], comorbidities of the patient and tumor behavior.
To integrate evidence-based data from trials with 
clinical observations about tumor biology could provide 
complementary information and help clinicians to 
individualize the treatment and to generate the optimal 
sequence for each patient.
New and promising agents, such as immune based 
therapies, continue to be explored; data from ongoing trial 
will help to develop more effective therapeutic strategies 
and new algorithms.
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